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ORIGINAL RESEARCH
Novel Guidewire Design and Coating for 
Continuous Delivery of Adenosine During 
Interventional Procedures
Mervyn B. Forman, MD, PhD; Erik C. Brewer, PhD; Zachary R. Brown, PhD; Elizabeth V. Menshikova, PhD; 
Anthony M. Lowman, PhD; Edwin K. Jackson , PhD 
BACKGROUND: The “no-reflow phenomenon” compromises percutaneous coronary intervention outcomes. There is an unmet 
need for a device that prevents no-reflow phenomenon. Our goal was to develop a guidewire platform comprising a nondis-
ruptive hydrophilic coating that allows continuous delivery of adenosine throughout a percutaneous coronary intervention.
METHODS AND RESULTS: We developed a guidewire with spaced coils to increase surface area for drug loading. Guidewires 
were plasma treated to attach hydroxyl groups to metal surfaces, and a methoxy–polyethylene glycol–silanol primer layer was 
covalently linked to hydroxyl groups. Using polyvinyl alcohol, polyvinyl pyrrolidone, and polyvinyl acetate, a drug layer con-
taining jet-milled adenosine was hydrogen-bonded to the polyethylene glycol–silanol layer and coated with an outer diffusive 
barrier layer. Coatings were processed with a freeze/thaw curing method. In vitro release studies were conducted followed 
by in vivo evaluation in pigs. Coating quality, performance, and stability with sterilization were also evaluated. Antiplatelet 
properties of the guidewire were also determined. Elution studies with adenosine-containing guidewires showed curvilinear 
and complete release of adenosine over 60 minutes. Porcine studies demonstrated that upon insertion into a coronary artery, 
adenosine-releasing guidewires induced immediate and robust increases (2.6-fold) in coronary blood flow velocity, which 
were sustained for ≈30 minutes without systemic hemodynamic effects or arrhythmias. Adenosine-loaded wires prevented 
and reversed coronary vasoconstriction induced by acetylcholine. The wires significantly inhibited platelet aggregation by 
>80% in vitro. Guidewires passed bench testing for lubricity, adherence, integrity, and tracking.
CONCLUSIONS: Our novel drug-releasing guidewire platform represents a unique approach to prevent/treat no-reflow phenom-
enon during percutaneous coronary intervention.
Key Words: adenosine ■ cardiac guidewire ■ no-reflow phenomenon ■ percutaneous coronary intervention
In spite of numerous advances in pharmacologic mo-dalities to modify associated risk factors, coronary artery disease remains a major cause of morbidity 
and mortality.1 Because of the advent of drug-eluting 
stents and technical advances in equipment, percuta-
neous coronary intervention (PCI) has rapidly evolved 
as the most common modality to treat coronary ar-
tery disease.2 Unfortunately, however, microvascular 
obstruction (MVO) and the “no-reflow phenomenon” 
(NRF) remain important obstacles to achieving op-
timal tissue perfusion after PCI. MVO and NRF are 
particularly problematic in anterior ST-segment–eleva-
tion myocardial infarction (STEMI) and saphenous vein 
grafts.3–5 Magnetic resonance imaging studies empha-
size the role of MVO as an independent risk factor for 
major cardiovascular events with a greater predictive 
power than ejection fraction or infarct size.6–8
The mechanisms responsible for MVO are complex 
and multifactorial and include embolization by ather-
omatous and thrombotic debris, release of potent 
vasoconstrictive substances, platelet aggregation, ac-
tivation of immune cells resulting in leukocyte plugging 
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and endothelial cell disruption of microvessels.3–5 
Since current vascular devices are only partially effec-
tive in preventing vascular and organ damage and do 
not reduce mortality, there is a dire need to develop 
new technologies to improve outcomes after PCI.9–12
Adenosine is an endogenous nucleoside that ac-
tivates 4 well-characterized receptors. Adenosine 
preserves microcirculatory flow by (1) preventing and 
reversing constriction of the coronary microcircula-
tion induced by numerous vasoconstrictors including 
thromboxane A2, platelet-activating factor, angiotensin 
II, norepinephrine, and endothelin-1; (2) inhibiting ac-
tivation of leukocytes; (3) inhibiting platelet activation; 
(4) blocking release of myeloperoxidase; (5) prevent-
ing calcium overload; and (6) reducing production of 
oxygen free radicals.4,5 Indeed, case reports suggest 
that intracoronary adenosine does reverse MVO/
NRF.13 While the majority of experimental and clini-
cal studies demonstrate beneficial effects of continu-
ous infusions of adenosine on enhancing myocardial 
salvage and improving microvascular flow, it is likely 
that the full therapeutic potential of adenosine is com-
promised because of adenosine’s ultra-short half-life 
(≈1 second) in blood and because of the dilution of the 
administered adenosine when delivered via a guiding 
or balloon catheter.4,5 We therefore conceived the idea 
that since the guidewire is the first mandatory device 
placed for PCI, incorporation of adenosine on the 
guidewire would allow immediate and targeted contin-
uous release of adenosine throughout the procedure 
and improve post-PCI perfusion.
In our initial attempt, we developed a nontoxic pen-
tameric form of adenosine using polyurethane technol-
ogy.14 While cumulative adenosine release and modest 
in vivo coronary vasodilatation was demonstrated on 
micro-machined guidewires, it became apparent that 
it would not be an acceptable solution for 2 reasons. 
First, the surface area of the guidewire was small, re-
sulting in an insufficient drug load. Second, the coating 
was degradable and exhibited poor lubricity, durability, 
and adhesive properties compared with guidewires 
with hydrophilic coatings. We therefore changed direc-
tions to address the inadequacies of the first iteration. 
This paper describes in detail an innovative device 
platform to include a new guidewire design and novel 
hydrogel coating that allows sufficient quantities of ad-
enosine to be released over a typical PCI procedure to 
produce robust vasodilatation and reversal of severe 
pharmacologically induced vasoconstriction in the 
porcine model. Confirmation of coating lubricity, ad-
herence, and durability and guidewire performance of 
the “Adenowire” is also presented.
METHODS
For data and for additional information on analytic 
methods or study materials, contact E.K. Jackson at 
edj@pitt.edu.
Guidewire Design
In preliminary studies, we determined that although 
micro-machined guidewires could elute adenosine, 
use of traditional guidewire designs, because of limited 
surface area, could not provide an optimal drug load.14 
In collaboration with 2 leading wire manufacturers 
(Asahi-Intecc, Justin, CA; and Lake Region Medical, 
Chaska, MN), we successively modified their popular 
wire designs by increasing the coil spacing in the distal 
15 cm of the wire to 0.005 inches while maintaining the 
wire performance and characteristics of the predicated 
CLINICAL PERSPECTIVE
What Is New?
• Microvascular obstruction and the no-reflow 
phenomenon are major barriers that preclude 
optimal outcomes in patients undergoing per-
cutaneous coronary interventions.
• Drawing upon numerous technologies, we have 
developed an adenosine-releasing guidewire 
that has the potential to prevent and treat mi-
crovascular obstruction and no-reflow phenom-
enon, thus greatly improving patient outcomes.
What Are the Clinical Implications?
• Our novel adenosine-releasing guidewire pro-
vides for an autonomous adenosine-releas-
ing system that performs without thought or 
planning.
• Therefore, by using Adenowires, the interven-
tionalist can protect patients from microvascu-
lar obstruction and the no-reflow phenomenon 
without altering their workflow.
• Adenowires have considerable translational 
potential.
Nonstandard Abbreviations and Acronyms
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device. Detailed drawings of the 2 wires are shown in 
Figure 1. The wires are made of stainless steel and con-
tain a coil spacing zone of 150 mm, with slight variation 
in the placement of the radiopaque tungsten-platinum 
marker. The coil-wound section was left uncoated, 
with the solid mandrel covered with proprietary Teflon. 
Mechanical testing requirements of both wires (tensile 
testing of all joints, torque strength, torqueability, tip 
flexion, and biocompatibility) met all the acceptance 
criteria and were similar to the predicate device.
Hydrogel-Drug Coating
The proposed chemical reactions involved in coating 
the wire are illustrated in Figures  2–5. The materials 
used for coating were polyvinyl alcohol (PVA; Mowiol 
28-99, MW 145 kDa; EMO Millipore, Billerica, MA), pol-
yvinyl acetate (PVAc; Kollicoat SR 30D; Sigma-Aldrich, 
St. Louis, MO), polyvinyl pyrrolidone (PVP; Providone 
K-30; Spectrum Chemical, New Brunswick, NJ), 
methoxy–polyethylene glycol (PEG)-silane (Jenkem 
Technology, Plano, TX), and adenosine (Sigma-
Aldrich). Coronary guidewires were cleaned in the dis-
tal 20- to 30-cm coiled region with an ultrasonic probe 
for 5 minutes in ethanol followed by deionized water 
for 5 minutes and dried via a nitrogen gas line as previ-
ously described.15–17 The wires were then subjected to 
oxygen plasma treatment for 2 minutes using a com-
mercial device (PE25-JW; Plasma Etch, Carson City, 
NV), which resulted in deposition of hydroxyl groups 
on the surface (Figure 2, reaction 1).18 A primer layer 
was then deposited on the wire utilizing methoxy-
PEG-silane (MW, 20  kDa). In this regard, a solution 
of methoxy-PEG-silane (40  mg/mL) was prepared in 
an ethanol/water solution (95/5 w/w) that was titrated 
to a pH of 5.0 with glacial acetic acid. After 30 min-
utes to allow the methoxy-PEG-silane to hydrolyze 
(Figure 3, reaction 2), the wires were dipped in the hy-
drolyzed methoxy-PEG-silane mixture (now methoxy-
PEG-silanol solution) for 1 hour and cured at 70°C for 
90 minutes in a vacuum oven set at <0.1 bar. As shown 
in Figure  4 (reaction 3), the silanol groups covalently 
bond to the hydroxyl groups on the stainless steel and 
crosslink with neighboring silanol moieties to form a 
robust primer layer.
Next, the inner drug layer was prepared. To accom-
plish this, a 20% w/w solution of PVA/PVP (99:1 mass 
ratio) in deionized water was prepared and autoclaved 
for 1 hour while stirring. This yielded a supersaturated 
solution that was homogeneous and free of bubbles. 
Using a water bath, the temperature of the PVA/PVP 
solution was maintained at 65°C. A 25% concentration 
of adenosine was required in the drug layer to provide 
a sufficient drug load on the wire. However, adenosine 
has poor solubility in water (80 mg/mL), making it dif-
ficult to achieve this concentration of adenosine in the 
drug layer. Moreover, commercial adenosine has a mean 
particle size of 55 μm which would have compromised 
Figure 1. The diagrams illustrate 2 types of 0.014-inch stainless steel guidewires used in the present study.
Adenosine-releasing guidewires are redesigns of 2 popular commercially approved wires (0.014-inch stainless steel), which have 
been modified by increasing the coil spacing to 0.005 inches in the distal 15 cm to accommodate the hydrophilic-drug polymer. In (A) 
the radiopaque platinum-tungsten portion is incorporated in the mandrel and in (B) is in the 3 cm of tightly wound coil at the tip. C, A 
micrograph of the redesigned 0.005-inch coils before coating. D, Micrograph of the 0.005-inch coils after coating with the polyethylene 
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the lubricity of the wire. To overcome these barriers, 
we utilized a 2-pass jet-milling process to reduce the 
solid-phase adenosine particles to <5 μm. Micronized 
adenosine was mixed in deionized water, sonicated for 
15 minutes, and then added to the PVA/PVP mixture, 
and the PVA/PVP/adenosine mixture was stirred until a 
homogeneous mixture was obtained. This resulted in a 
mixture that contained 7.5% PVA, 67.5% water, and 25% 
adenosine, which was kept at 65°C for the duration of 
the coating process. Next, the guidewire coated with the 
PEG-silanol primer was coated with the adenosine-con-
taining hydrogel. Multiple hydroxyl groups in the hydrogel 
form hydrogen bonds with multiple ether, carbonyl and 
amine groups in the primer, thus creating an extensive 
network of hydrogen bonds between the drug-contain-
ing hydrogel layer and the primer layer (Figure 5, reaction 
4). This results in a stable attachment of the drug layer 
with the wire surface. Laser diffraction and optical mi-
croscopy demonstrated stable particle sizes of the jet-
milled adenosine even after 1 week in the hydrogel.
The outer barrier layer was produced using PVA 
with PVAc in a ratio of 1:3 (w/w). A 20% solution of 
PVA without PVP was prepared as described above. 
Commercially available PVAc packaged as a 30% dis-
persion with stabilizers and excipients was added to 
the PVA solution and mechanically mixed at 65°C to 
achieve a homogeneous solution. The final solution, 
consisting of 5% PVA, 80% deionized water and 15% 
PVAc, was left at room temperature.
The wires were coated using a mechanical dipper 
(Precision Dip Coater QPI-168; Qualtech, Denver, CO), 
with insertion and withdrawal parameters set to obtain 
a total polymer weight of ≈45 mg per 10-cm length of 
wire. For the drug layer, an insertion rate of 200 mm/
min, dwell time of 10 seconds, and withdrawal rate of 
40  mm/min was employed. After applying the drug 
layer, the wire was immediately flash frozen in liquid ni-
trogen and subjected to a 60-minute freeze/thaw cycle: 
45 minutes at −20°C, followed by thawing at room tem-
perature. This freeze/thaw cycle was then repeated 
to harden the gel. The wire was then coated with the 
barrier layer using a withdrawal rate of 500 mm/s, after 
which the wire was subjected to a further 2 freeze/thaw 
cycles. The final product contained a total polymer 
weight per 10-cm length of wire of ≈40 to 45 mg with a 
drug load of 2.7±0.2 mg of adenosine per 10-cm length 
of wire.
In Vitro Release Studies
These studies (n=6) were performed in 0.9% saline 
rather than in plasma or blood because adenosine 
has a short half-life (seconds) in the latter 2 media, 
making detection difficult. Tubes containing 15 mL of 
saline were maintained at 37°C, and 10  cm of the 
spaced coiled section of the guidewire was placed 
serially in tubes for 0 to 5, 5 to 10, 10 to 20, 20 to 
30, 30 to 40, 40 to 50, and 50 to 60 minutes. One-
milliliter samples were then taken from the tubes 
to measure the concentration of adenosine by 
spectrophotometry.19
Figure 2. Reaction 1: guidewires were initially exposed to 
plasma treatment to create OH groups on the stainless steel 
surface. 
Figure 3. Reaction 2: methoxy–polyethylene glycol (PEG)-
silane was treated with acid to hydrolyze the ester linkages, 
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Animal Studies
All porcine studies were approved by Institutional 
Animal Care and the Committee of Synchrony Labs 
LLC (Durham, NC). Yucatán mini pigs (male and 
female, 25–30  kg, 6  months of age) were premed-
icated with Telazol (5 mg/kg). Anesthesia was main-
tained with 1% isoflurane and supplemental oxygen 
to maintain a pH of 7.4±0.6. Animals received aspi-
rin 300  mg orally for 3  days before the study and 
were anticoagulated throughout the procedure with 
heparin (150 units/kg) to maintain activated clotting 
time >300. Heart rate, ECG changes, and blood 
pressure were monitored continuously using leads I, 
aVF, and aVL with a 6 F sheath in the left femoral ar-
tery. Another sheath was placed in the right femoral 
artery for coronary intubation of the left main ves-
sel using a 6 F HS guide catheter. Coronary blood 
flow velocity (CFV) was measured using a 0.014-inch 
Doppler flow wire (Combowire; Volcano Corporation, 
Rancho Cordova, CA) and dedicated software. CFV 
was measured as a continuous average pulse wave 
velocity over 4 seconds, and mean values were re-
corded every 60 seconds.
Two experimental protocols were employed. In 
the first protocol (n=8), we assessed the efficacy and 
duration of vasodilatation induced by the guidewire 
under basal conditions. The Combowire was posi-
tioned in either the proximal circumflex or left anterior 
descending coronary artery (LAD), and baseline CFV 
was measured after obtaining an optimal velocity 
tracing. Care was taken to ensure that the Doppler 
wire remained in the same position throughout the 
experiment. An adenosine-loaded guidewire was 
positioned in the distal circumflex coronary artery or 
LAD, and heart rate, blood pressure, and CFV was 
measured serially every minute for 30 minutes. The 
drug-coated wire was removed, and CFV was mea-
sured until it had returned to baseline. Serial coro-
nary angiography was performed at baseline, after 
Combowire placement and after removal of the med-
icated guidewire.
In the second protocol, we evaluated the ability 
of the wire to prevent and reverse intense vasocon-
striction induced by intracoronary administration 
of acetylcholine. Release of numerous potent va-
soconstrictors plays a key role in the pathogenesis 
of NRF. Acetylcholine is a powerful vasoconstric-
tor in the porcine model via direct muscarinic ac-
tivation of smooth muscle cells in small coronary 
Figure 4. Reaction 3: PEG-silanols condensed with OH 
groups both on the wire and on neighboring silanols to form 
a polymerized primer layer. 
Figure 5. Reaction 4: grafting of the polyvinyl alcohol/
polyvinyl pyrrolidone/polyvinyl acetate hydrogel to the primer 
layer is achieved via hydrogen bonding interactions between 
the carbonyl, ether and amine groups of polyethylene glycol 
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arteries resulting in NRF.20 A Transit infusion catheter 
(Codman, Roynham, MA) was placed in the proxi-
mal LAD for the drug infusion. Acetylcholine doses 
of 0.3 to 1.0 mg/min were infused into the LAD for 
20 to 30  minutes. Preliminary studies showed that 
this results in an ≈80% reduction in CFV. In some 
studies, acetylcholine was commenced initially and 
after a >50% decrease in CFV was observed, an ad-
enosine-loaded guidewire was rapidly inserted into 
the distal vessel for 15 to 20 minutes. These studies 
were designed to determine if the wire could reverse 
the NRF. In other experiments, we evaluated whether 
an adenosine-releasing wire could prevent the NRF 
by placing the adenosine-loaded wire initially into the 
LAD. Once an increase in CFV had occurred, an ace-
tylcholine infusion was begun for 20 to 30 minutes. 
In some studies, the wire was removed at 20  min-
utes and the acetylcholine infusion continued, while 
in others the acetylcholine infusion was terminated 
and the wire was left in place for a further 10 minutes 
in the vessel.
Evaluation of Wire Performance, Coating 
Quality, and Integrity
Because guidewires are used to place a device 
into coronary vessels, it is essential that they easily 
negotiate a tortuous vasculature to facilitate place-
ment of devices without inducing vascular damage. 
To assess guidewire lubricity, a 2-dimensional cor-
onary model system (ASTM 2394) and a MSI IDTE 
3000 device with dedicated software were utilized 
(Machine Solutions, Flagstaff, AZ). A 6 F coronary 
guide catheter was introduced 3 cm into the mock 
vessel. The wire was inserted through a hemostatic 
valve into the catheter and tracked for 3 cycles in 
the model for a distance of 38 cm. A proximal load 
cell with an encoder was used to measure the force 
applied to deliver and retract the guidewire and the 
distance in and out of the model. Microscopic im-
ages were obtained at baseline, after the track test 
and after hydration for 1 hour. Wire performance was 
determined in vitro and in vivo and included the abil-
ity to navigate the model or vessel, torqueability, and 
tip flexibility.
Platelet Aggregation Studies
Human venous blood was obtained from 4 healthy 
donors who had not taken any medications known 
to influence platelet function for at least 2  weeks 
before the study and as described by Gurbel and 
coworkers.21 Procedures were performed accord-
ing to institutional research committee standards, 
and informed consent was obtained. Venous blood 
samples were collected into 3.2% trisodium cit-
rate Vacutainer tubes. After 15  minutes, the tubes 
were centrifuged at 200g for 10  minutes at room 
temperature to recover platelet-rich plasma (PRP). 
Platelet-poor plasma was then obtained by centri-
fuging PRP at 1500g for 10  minutes. Two hundred 
microliters of PRP were transferred to aggregation 
cuvettes with stir bars. One-centimeter pieces of 
guidewires with (Adenowire) and without adenosine 
(Control) were added to the cuvette and incubated 
in a multiple-channel optical aggregometer (Chrono-
Log Corp, Hovertown, PA) and stirred for 20  min-
utes. Two commercially available guidewires, BMW 
(Abbott Vascular, Santa Clara, CA) and Runthrough 
NS (Terumo, Tokyo, Japan), were also evaluated. 
Following incubation, PRP was transferred to fresh 
cuvettes with stir bars and aggregation was initiated 
by adding 2  µmol/L ADP or 1  µg/mL collagen and 
monitored for 6 minutes. Aggregation, using platelet-
poor plasma as a control reference, was assessed 
by the aggregometer software. Area under the ag-
gregation curve, maximum aggregation, slope of the 
aggregation curve, and the lag time between adding 
the agonist and onset of aggregation were the vari-
ables included in the analysis.
Statistical Analysis
Data are expressed as mean and SEM. Statistical 
analyses of the effects of Adenowires on heart rate; 
systolic, diastolic, and mean blood pressures; and 
CFV in porcine experiments (n=8) were conducted on 
data that were transformed by the Box-Cox method 
so as to meet the assumptions of ANOVA. In this re-
gard, assumptions of normality of groups and equal-
ity of variances among groups were tested using 
NCSS 2019 Statistical Software (Kaysville, UT;, ncss.
com/software/ncss). Box-Cox transformed porcine 
data were subjected to ANOVA for repeated meas-
ures (RM 1-Factor ANOVA) followed by the Bonferroni 
test (versus control) using NCSS 2019 Statistical 
Software. This multiple comparison test adjusts 
the comparison-wise error rate, (c), in such a way 
that the experiment-wise error rate, alpha(f), is kept 
at a predetermined level of P<0.05. With k means, 
there are k−1 comparisons with a control. Hence 
alpha(c)=alpha(f)/(2(k−1)). Sample size was based on 
our previous study in which we infused adenosine 
into the coronary artery of closed-chest dogs and 
obtained significant results with a sample size of 8.22 
R2 values were calculated by Prism version 8.4.3 for 
Windows (GraphPad Software, San Diego, CA; www.
graph pad.com). R2 is computed from the sum of the 
squares (SS) of the distances of the points from the 
best-fit curve determined by nonlinear regression 
(SSreg). SSreg is normalized to SS of the distances of 
the points from a horizontal line through the mean of 
all Y values (SStot). R
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RESULTS
In Vitro Adenosine-Elution Study
The cumulative elution of adenosine from 6 guidewires 
over 60 minutes is illustrated for each individual guide-
wire in Figure 6. Figure 7 depicts the cumulative aver-
age release from the composite of all 6 guidewires, with 
results expressed as either absolute release (top panel) 
or relative release (percentage of 60-minute time point; 
bottom panel). As shown, the release of adenosine was 
curvilinear with ≈60% released in the first 20  minutes 
and most of the remainder by 40 minutes. This release 
profile is optimal for a typical coronary interventional pro-
cedure, with the initial burst treating and the sustained 
release preventing NRF. The total amount of released 
adenosine was 2.7±0.2 mg/10-cm length of wire.
Effect of Adenosine-Releasing Guidewire 
on Basal Coronary Flow in the Pig
The effect of 8 guidewires on CFV in the circumflex 
coronary artery and LAD is shown in Figure 8A. CFV 
Figure 6. Line graphs demonstrate the elution profile of adenosine from 6 adenosine-loaded 
guidewires (Adenowires) in vitro.
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increased within 1  minute of guidewire insertion and 
remained significantly elevated above baseline for 
27 minutes. This increase in CFV closely paralleled the 
adenosine-release profile in vitro. The fold increase in 
CFV (Figure 8B), a measure of coronary flow reserve, 
peaked at 2.5 and remained >2.0 for 15 minutes after 
wire insertion. Previous studies in our laboratory showed 
that a continuous infusion of adenosine into the LAD at 
50 µg/kg per minute increased CFV ≈250%. Insertion 
of adenosine-releasing guidewires did not affect ei-
ther mean arterial blood pressure (Figure 8C) or heart 
rate (Figure 8D), and no animal developed heart block. 
Coronary angiography after each guidewire removal 
showed normal flow and no filling defects (Figure 9).
Effect of Adenosine-Releasing Guidewire 
on Acetylcholine-Induced Coronary 
Vasoconstriction in the Pig
Figure 10 summarizes the results of 3 experiments in 
which acetylcholine was infused into the coronary ar-
tery to induce coronary vasoconstriction, and then an 
adenosine-releasing guidewire was inserted. In the first 
experiment of this type (Figure 10A and 10B), coronary 
vasoconstriction was so intense that coronary flow 
ceased and the animal rapidly developed ventricu-
lar fibrillation. The heart was immediately defibrillated 
and an adenosine-releasing wire was inserted into the 
coronary artery. Despite continuing the acetylcholine, 
immediately upon insertion of the adenosine-releasing 
wire, CFV not only was restored but more than dou-
bled from pre-acetylcholine baseline. CFV gradually 
returned to baseline and the acetylcholine infusion was 
stopped, and then the guidewire was removed. In 2 
similar experiments (Figure 10C through 10F), insertion 
of the adenosine-releasing guidewire immediately re-
versed acetylcholine-induced coronary vasoconstric-
tion and maintained CFV either above or near baseline 
during the acetylcholine infusion. Together, Figures 
11 and 12 summarize the results of 5 experiments in 
which an adenosine-releasing guidewire was inserted 
before infusing acetylcholine into the coronary artery. 
As shown, in all experiments, insertion of the guidewire 
increased CFV and maintained CFV above baseline 
even when acetylcholine was infused. The experi-
ment in Figure 12C was particularly striking. Here, the 
adenosine-releasing guidewire elevated CFV above 
baseline even while acetylcholine was infused. While 
maintaining the acetylcholine infusion, the guidewire 
was removed, and CFV rapidly began to fall nearly to 
zero. Coronary angiography in 2 animals showed acute 
NRF, with restoration of coronary patency after inser-
tion of an adenosine-releasing guidewire (Figure 13).
Evaluation of Guidewire and Coating 
Performance
Light microscopy of unused wires (Figure 1) demon-
strated that the hydrogel-drug coating filled the coil 
spaces and provided a smooth and thin coating on 
the outer coil surface. Track forces were obtained 
on 4 Adenowires and 3 predicated hydrophilic wires 
(Prowater; Asahi-Intecc, Justin, CA). Note that the 
frictional forces to deliver and retract the Adenowires 
were similar to the commercial wires indicative of simi-
lar lubricity properties (Figure  14). Light microscopy 
after track tests and hydration revealed that the coat-
ing integrity remained unchanged, with no evidence of 
swelling or coating loss.
Platelet Aggregation
Because a 1-cm length of an Adenowire contains 
≈0.27 mg of adenosine, the concentration of adeno-
sine present in the 0.2 mL of PRP would be estimated 
to be 5 mmol/L assuming total release of adenosine 
(0.27 mg/0.2 mL=1350 mg/L=5 mmol/L). Thus, there 
should be a sufficient concentration of adenosine to 
attenuate platelet activation. Figure  15 illustrates the 
Figure 7. Line graphs depict the average elution profile 
from the 6 adenosine-loaded guidewires shown in Figure 6.
The results are plotted either as cumulative release of absolute amounts 
of adenosine (top panel) or as % release relative to the 60-minute 
time point (bottom panel). The average release at 60  minutes was 
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effects of Adenowires and Control wires (wires coated 
with the novel coating formulation but without adeno-
sine) on area under the aggregation curve, maximum 
aggregation, rate of aggregation (slope), and lag time 
between addition of agonist and the onset of aggre-
gation. Note that coated wires containing adenosine 
(Adenowires) resulted in a striking inhibition of ADP-
induced and collagen-induced platelet aggregation as 
assessed by the reduction in area under the aggrega-
tion curve, maximum aggregation, and rate of aggre-
gation. In addition, Adenowires delayed aggregation 
in response to collagen. Unexpectedly, Control wires 
exerted antiplatelet effects that were similar to, but not 
quite as striking as, Adenowires. Moreover, Control 
wires exerted more efficacious platelet inhibition com-
pared with 2 commercially available hydrophilic wires 
(area under the aggregation curve: Control wires, 
116±30 versus commercial wires, 258±32, P<0.05; 
maximum aggregation: Control wires, 28±6 versus 
commercial wires, 62±8; P<0.05).
DISCUSSION
Guidewires are the first mandatory device placed in 
the culprit vessel before any interventional procedure. 
Current guidewires are coated with inert hydrophilic 
compounds such as PVP, polyacrylamides, and hyalu-
ronic acid to enhance the lubricity and trackability. Here, 
we developed a platform guidewire to deliver adenosine 
without dissolution or disruption of the coating.
Our design employed a unique guidewire micro-
structure and a novel combination of coating technolo-
gies, as well as jet-milled adenosine. Since no data exist 
regarding formulations for drug-eluting guidewires, we 
developed a matrix (reservoir) system employing an 
Figure 8. Line graphs summarize the effects on coronary flow velocity (CFV) of adenosine-
releasing guidewires (n=8) inserted into the LAD or circumflex coronary artery of Yucatan mini-
pigs.
Coronary flow velocity (A) was markedly increased immediately upon wire insertion and remained 
significantly elevated for 33  minutes. B, The fold increase in CFV, which equates to coronary flow 
reserve. The coronary flow reserve was >2.0 for the first 15 minutes. The small spike in CFV when the 
guidewire was removed was likely attributable to an incremental surge in adenosine release caused by 
wire manipulation. The adenosine-releasing wire did not affect mean blood pressure (MABP) or heart rate 
(C and D, respectively). Values are means and SEMs. RM 1-Factor ANOVA indicates repeated measures 
1-factor analysis of variance. Bonferroni indicates Bonferroni test for comparisons to baseline (control) of 
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inner drug-containing layer and an outer barrier layer. 
PVA has been used in other applications because it 
is nontoxic, noncarcinogenic, bioadhesive, and elas-
tic.23,24 The crystalline nature of PVA allows physical 
cross-linking by repeated cycles of freezing and thaw-
ing with pore size altered by the number of cycles and 
molecular weight.23 As cross-linking is not stable, our 
group developed the concept that the addition of PVP 
would stabilize the hydrogel network through hydro-
gen bonding between carbonyl groups of PVP and 
hydroxyl groups of PVA.25 In preliminary studies, we 
established that a PVA:PVP ratio of 99:1 provides both 
optimal mechanical stability and the best elution profile 
and was therefore used as the formulation for the inner 
drug layer of the coating.
Jet milling of adenosine was required to reduce 
the solid-phase particle size to obtain a smooth, lu-
bricious coating. To optimize drug release for a typ-
ical PCI procedure, we determined that the addition 
of PVAc, a more hydrophobic polymer, was required 
for the barrier layer. PVAc is commercially available as 
a 30% dispersion that includes sodium lauryl sulfate 
as a wetting solution (Kollicoat; BASF, Florham, NJ, 
USA).26 Following numerous trials, we determined that 
a ratio of PVAc:PVA of 3:1 in the outer barrier layer re-
sulted in an optimal release profile. Light and scanning 
electron microscopy showed a smooth surface with a 
thin outer coating diameter of a few microns. Bench 
testing examined lubricity, durability, and integrity and 
determined that these important parameters met Food 
and Drug Administration standards. Also, in prelimi-
nary tests we found that electron-beam sterilization of 
the adenosine-releasing wires did not affect release 
kinetics.
In vitro studies demonstrated a curvilinear elution 
of adenosine over 60  minutes with a drug load of 
2.7±0.2 mg per 10 cm of wire length. Porcine stud-
ies confirmed a robust pharmacologic effect with 
an immediate and significant increase in CFV for 
30 minutes. The percentage increase in velocity, an 
estimate of coronary flow reserve, was 2.5 during the 
first 10 minutes of insertion, which is comparable to 
a 50 µg/kg per minute intracoronary infusion of ade-
nosine in this model (M.B. Forman, unpublished data, 
2018). Further studies using intracoronary infusions 
of acetylcholine to induce severe vasoconstriction of 
the microvasculature demonstrated that insertion of 
the adenosine-releasing guidewire both prevented 
and reversed the acetylcholine-induced decreases in 
CFV. The efficacy of the adenosine-releasing guide-
wire to immediately restore normal coronary perfu-
sion was illustrated in 1 animal that developed acute 
NRF and severe ischemia, which was immediately 
reversed after wire insertion.
Since only a 5- to 6-cm length of guidewire could 
be placed in the pig coronary arteries, it is probable 
that the coronary vasodilatory response would be even 
greater in humans because human coronary arteries 
would accommodate at least 9 cm of the guidewire. 
Adenowire insertion into pig coronary arteries did not 
cause systemic hemodynamic effects, arrhythmias, or 
heart block. Nonetheless, because Adenowires likely 
would deliver more adenosine to patients because 
of the greater length of wire in the coronary arteries, 
going forward it will be important to carefully examine 
the effects of Adenowires on hemodynamics and ar-
rhythmias in patients before manipulations, when con-
trast medium is injected, and when a stent or balloon 
is used in an actual PCI.
Platelets play a key role in MVO through release 
of potent vasoconstrictor substances such as sero-
tonin, thromboxane A2, and platelet-activating factor. 
Adenosine, through activation of high-affinity A2A re-
ceptors, markedly inhibits platelet aggregation. Not sur-
prisingly, in vitro studies demonstrated that Adenowires 
significantly inhibited platelet aggregation. However, 
we did not expect that the naïve coating alone, with-
out adenosine, would also exert antiplatelet effects 
Figure 9. Coronary angiogram of circumflex in left anterior oblique projection.
A, Baseline; (B) adenosine guidewire positioned in distal vessel with radio-opaque tip (solid red arrow) 
clearly visible; (C) post wire removal after 30 minutes showing normal flow. Also shown (dashed yellow 
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when compared with commercial hydrophilic wires. 
Since coadministration of A2A agonists enhances the 
antiplatelet effects of P2Y12 antagonists, Adenowires 
could provide additional benefits to reduce thrombus 
formation and embolization during PCI in clinical set-
tings with large thrombus formation.27
MVO and NRF remain important obstacles that 
frustrate achievement of optimal tissue perfu-
sion after PCI. All patients, irrespective of clinical 
presentation, are at risk for NRF, which occurs in 
4% to 8% of elective procedures.4,5 However, NRF 
is most prevalent in the setting of STEMI. In this 
regard, NRF manifests in >50% of patients with 
STEMI with anterior infarctions.4,5,28 MVO is asso-
ciated with larger infarct size, abnormal ventricular 
remodeling, arrhythmias, and CHF.4,5,28 Moreover, 
MVO is an independent risk factor for major cardio-
vascular events with greater predictive power than 
Figure 10. Line graphs summarize 3 experiments in which acetylcholine was infused into the 
coronary artery before the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); experiment 2 in (C and D); and experiment 3 in (E and F). Coronary 
flow velocities (CFV) are illustrated in (A, C, and E) and associated mean arterial blood pressures (MABPs) 
are shown in (B, D, and F). In experiment 1, the animal developed severe ischemia that induced ventricular 
fibrillation requiring cardioversion. In all 3 experiments, acetylcholine caused coronary vasoconstriction 
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ejection fraction or infarct size.6,7,29 The mechanisms 
responsible for MVO are complex and include em-
bolization by atheromatous and thrombotic debris, 
release of potent vasoconstrictors, and activation 
of the immune system resulting in leukocyte plug-
ging and endothelial disruption of microvessels.3–5 
The realization that prevention and prompt reversal 
of MVO is paramount to improve outcomes in high-
risk PCI procedures has motivated the evaluation 
of numerous devices to ameliorate MVO. Various 
mechanical devices that induce thrombectomy, as-
pirate clots, or protect against emboli have failed to 
consistently reduce MVO, infarct size, or mortality, 
suggesting that they are not protective throughout 
Figure 11. Line graphs summarize 3 experiments in which acetylcholine was infused into the 
coronary artery after the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); experiment 2 in (C and D); and experiment 3 in (E and F). 
Coronary flow velocities (CFVs) are illustrated in (A, C, and E) and associated mean arterial blood 
pressures (MABPs) are shown in (B, D, and F). In all 3 experiments, insertion of the adenosine-releasing 
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the whole procedure and do not affect humoral 
factors and cytotoxic compounds responsible for 
MVO.9–12
Given the negative impact of inadequate tissue per-
fusion with PCI, there is increased awareness of the 
need for new pharmacologic approaches to prevent 
Figure 12. Line graphs summarize 2 additional experiments in which acetylcholine was infused 
into the coronary artery after the adenosine-loaded guidewire was inserted into the artery.
Experiment 1 is summarized in (A and B); and experiment 2 in (C and D). Coronary flow velocities (CFVs) 
are illustrated in (A and C) and associated mean arterial blood pressures (MABPs) are shown in (B and 
D). In both experiments, insertion of the adenosine-releasing guidewire immediately increased CFV and 
prevented acetylcholine from reducing CFV below baseline. Note that in (C) removal of the adenosine-
releasing guidewire while maintaining the intracoronary infusion of acetylcholine resulted in a rapid and 
profound decline in CFV.
Figure 13. Coronary angiography showing an example of the no-reflow phenomenon (NRF) reversed by an adenosine-
releasing guidewire.
A, A baseline angiogram was obtained with the Combowire (dashed yellow arrow) in the proximal LAD. B, Soon after administration of 
acetylcholine, severe NRF occurred with total cessation of blood flow in the proximal LAD (solid red arrow). C, Upon placement of an 
adenosine-releasing guidewire (solid purple arrow) in the LAD, coronary flow was rapidly restored and maintained even while infusing 
acetylcholine for an additional 20 minutes. D, After stopping acetylcholine and removing the guidewire, a final angiogram showed that 
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and reverse MVO. Adenosine is an endogenous nu-
cleoside that activates 4 well-characterized receptors, 
producing a myriad of physiological effects that main-
tain microcirculatory flow.4,5,30 These include potent 
vasodilatory, antiplatelet, and anti-inflammatory ac-
tions, restoration of profibrinolytic activity of endothelial 
cells, acceleration of vascular healing (vasculogenesis), 
and stimulation of new vessel formation (angiogene-
sis).4,5,31 Adenosine also functions as an endogenous 
cardioprotective agent as established by the fact that 
adenosine is the mediator of pre- and postcondition-
ing.5 Activation of adenosine receptors stimulates sur-
vival kinases, which prevent opening of mitochondrial 
permeability transition pores.5 These actions, in asso-
ciation with adenosine’s antiapoptotic effects, prevent 
lethal myocyte injury. Indeed, in the acute myocardial 
infarction study of adenosine trial, a 3-hour intrave-
nous infusion of adenosine significantly reduced infarct 
size in patients with anterior STEMI, and intracoro-
nary or repeated boli of adenosine reduced MVO in 
STEMI and saphenous vein grafts.5,27,32–35 The multiple 
mechanisms whereby adenosine attenuates MVO and 
cellular injury, which have been verified in numerous 
clinical studies, indicate that adenosine is superior to 
other pharmacologic agents for preventing and treat-
ing MVO.
In humans, adenosine has a plasma half-life of 
only ≈1  second. Despite the potential therapeutic 
benefits of adenosine in STEMI, the short half-life of 
adenosine is problematic because it mandates that 
adenosine be delivered by continuous administra-
tion to optimize its beneficial effects on MVO and 
infarct size. Moreover, intravenously administered 
adenosine induces unpleasant, and in some cases 
serious, side effects. Thus, there is a dire need to 
develop a convenient system that allows continuous 
delivery of adenosine in pharmacologic amounts 
directly into the coronary circulation while avoiding 
adverse effects. Since guidewires are the first man-
datory device placed in the culprit vessel before PCI, 
an adenosine-releasing guidewire provides for an 
autonomous system that performs without thought 
or planning. In this regard, our adenosine-releasing 
guidewire is a platform guidewire product coated 
with a novel hydrophilic coating that allows delivery of 
a drug, without disruption of the coating, throughout 
the interventional procedure. This guidewire achieves 
high concentrations of adenosine at the target site, 
thereby optimizing pharmacologic efficacy yet avoid-
ing side effects that would be induced with high-dose 
systemic administration. Moreover, since adenos-
ine release is immediate, our adenosine-releasing 
Figure 14. Track forces (g) of 4 Adenowires and 3 commercial wires with a proprietary hydrophilic 
coating is illustrated.
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guidewire would promote preconditioning in patients 
with STEMI before reperfusion of the myocardium 
following balloon or stent placement.
In conclusion, here we describe a therapeutic 
agent–releasing guidewire platform that allows for 
continuous release of pharmacologic amounts of ad-
enosine directly into the microvasculature during a 
PCI procedure. The average time for the total PCI pro-
cedure is ≈60 minutes from start to finish. However, 
once the guide catheter has been positioned in the 
coronary ostium, guidewire insertion into the culprit 
vessel for placement of balloon and stent catheters 
rarely exceeds 30 minutes, even with complex lesions 
and acute coronary occlusions; thus, the current de-
sign of the Adenowire allows for the appropriate time 
frame for release of pharmacologic amounts of ade-
nosine. In the present study, there was a small spike 
in CFV when the guidewire was removed; this was 
likely attributable to an incremental surge in adenos-
ine release caused by wire manipulation. If this occurs 
in the human coronary circulation during balloon and 
stent insertion, it would be beneficial since a surge 
of adenosine during these critical moments would be 
advantageous. The portion of the Adenowire in the 
guide catheter would also elute adenosine, and thus 
extra adenosine would be delivered with injection of 
contrast material; this design is also a plus. The de-
velopment of this guidewire necessitated optimization 
of the surface area of the guidewire, use of novel hy-
drophilic and hydrophobic polymers, and creation of 
a reservoir (matrix) system comprising an inner drug 
layer and outer barrier layer. In vitro studies confirmed 
an ideal elution profile for adenosine that was veri-
fied in a large animal model where robust coronary 
vasodilatation and rapid reversal of vasoconstriction 
was demonstrated. Bench studies revealed that wire 
performance and coating quality (lubricity, durabil-
ity, adhesion, and integrity) were comparable to inert 
hydrophilic guidewires. The novel inert coating also 
provides antiplatelet effects that were amplified with 
the addition of adenosine in the coating. Although 
we have not yet performed biocompatibility testing, 
the safety of PVA and PVAc is well established, as 
they are used as tissue replacement material and in 
drug and food products.23–26 This technology could 
be used on a pressure wire to measure fractional flow 
Figure 15. Effects of Adenowires and Control wires (wires coated with the novel coating formulation but without adenosine) 
on area under the aggregation curve (AUC), maximum aggregation, rate of aggregation (slope) and lag time between addition 
of agonist and the onset of aggregation.
A, Representative platelet aggregation tracings showing aggregation responses to ADP (2 µmol/L), collagen (1 µg/mL), ADP+Adenowire, 
collagen+Adenowire, ADP+Control wire and collagen+Control wire. Adenowires were coated with our novel hydrophilic coating 
that contained adenosine; Control wires were similarly coated but did not contain adenosine. Bar graphs summarize the effects of 
treatments on (B) area under the aggregation curve, (C) maximum aggregation, (D) slope of the aggregation curve and (E) the lag 
time between adding the agonist and onset of aggregation. Note that Adenowires markedly inhibited platelet aggregation. The inert 
coating also manifested antiplatelet properties that was similar to, but not quite as efficacious as, Adenowires. Data were analyzed by 
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reserve, thereby avoiding the side effects of large in-
travenous infusions of adenosine. The coating formu-
lation would also be applicable for controlled release 
of other drugs for interventional procedures such as 
anti-thrombotic and anti-platelet agents, anticoag-
ulants and antimitotic agents. Furthermore, the pro-
cess could be employed to coat other devices such 
as vascular sheaths, catheters, balloons, and stents.
While the overall incidence of NRF is low (4%–8%), 
NRF remains prevalent in high-risk patients undergo-
ing procedures such as anterior STEMI and saphenous 
vein graft interventions. Furthermore, all patients, ir-
respective of a clinical presentation, are at risk. Since 
an Adenowire would add little to the overall cost of a 
procedure and since NRF is unpredictable, likely the 
cost-benefit ratio is favorable for use of the Adenowire 
as insurance against NRF.
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